Literature DB >> 21349364

Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients.

Massimiliano Fabbiani1, Simona Di Giambenedetto, Michela Sali, Salvatore Farina, Paola Sansonetti, Enrica Tamburrini, Lorenzo Zileri Dal Verme, Giovanni Delogu, Andrea De Luca, David Kelvin, Roberto Cauda, Giovanni Fadda.   

Abstract

Immunogenicity of influenza A (H1N1)v MF59-adjuvanted vaccine was studied in HIV-infected patients. The vaccine was effective in inducing a protective immune response in patients with a CD4 >200 cells/μL while individuals with CD4 <200 cells/μL showed lower rates of seroconversion and seroprotection. These results underscore the usefulness of immunization against influenza in HIV-infected patients, though a boosting dose of vaccine may be required in seriously immunocompromised patients.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21349364     DOI： 10.1016/j.vaccine.2011.02.020

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  8 in total

1.  Serological response to trivalent inactivated influenza vaccine in HIV-infected adults in Singapore.

Authors:  Yuk-Fai Lau; Lay-Hoon Tang; David Chien Lye; Eng-Eong Ooi; Yee-Sin Leo
Journal:  Hum Vaccin Immunother       Date:  2017-02-17       Impact factor: 3.452

2.  Adjuvanted-influenza vaccination in patients infected with HIV: a systematic review and meta-analysis of immunogenicity and safety.

Authors:  Yong-Chao Chen; Jia-Hao Zhou; Jia-Ming Tian; Bai-Hui Li; Li-Hui Liu; Ke Wei
Journal:  Hum Vaccin Immunother       Date:  2019-11-01       Impact factor: 3.452

3.  Unadjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected adults.

Authors:  Shuji Hatakeyama; Kiyoko Iwatsuki-Horimoto; Koh Okamoto; Yoko Nukui; Nahoko Yata; Akira Fujita; Shigeki Inaba; Hiroshi Yotsuyanagi; Yoshihiro Kawaoka
Journal:  Vaccine       Date:  2011-10-05       Impact factor: 3.641

4.  Vitamin D levels and influenza vaccine immunogenicity among HIV-infected and HIV-uninfected adults.

Authors:  Nancy F Crum-Cianflone; Seunghyun Won; Rachel Lee; Tahaniyat Lalani; Anuradha Ganesan; Timothy Burgess; Brian K Agan
Journal:  Vaccine       Date:  2016-08-28       Impact factor: 3.641

5.  Immune response to 2009 H1N1 vaccine in HIV-infected adults in Northern Thailand.

Authors:  Nuntisa Chotirosniramit; Patcharaphan Sugandhavesa; Linda Aurpibul; Sunida Thetket; Natthapol Kosashunhanan; Taweewat Supindham; Panuwat Wongkulab; Quanhathai Kaewpoowat; Kanokporn Chaiklang; Oranitcha Kaewthip; Piyathida Sroysuwan; Antika Wongthanee; Hatairat Lerdsamran; Pilaipan Puthavathana; Khuanchai Suparatpinyo
Journal:  Hum Vaccin Immunother       Date:  2012-08-21       Impact factor: 3.452

6.  Immunogenicity of Licensed Influenza A (H1N1) 2009 Monovalent Vaccines in HIV-Infected Children and Youth.

Authors:  Robert F Pass; Sharon Nachman; Patricia M Flynn; Petronella Muresan; Terence Fenton; Coleen K Cunningham; William Borkowsky; James B McAuley; Stephen A Spector; Elizabeth Petzold; Wende Levy; George K Siberry; Ed Handelsman; L Jill Utech; Adriana Weinberg
Journal:  J Pediatric Infect Dis Soc       Date:  2013-07-17       Impact factor: 3.164

Review 7.  Immunology and efficacy of MF59-adjuvanted vaccines.

Authors:  Eun-Ju Ko; Sang-Moo Kang
Journal:  Hum Vaccin Immunother       Date:  2018-08-29       Impact factor: 3.452

Review 8.  Influenza vaccination in HIV-positive subjects: latest evidence and future perspective.

Authors:  A Ceravolo; A Orsi; V Parodi; F Ansaldi
Journal:  J Prev Med Hyg       Date:  2013-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.